Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

23.20 +0.80 (+3.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rapport Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
From Rapport Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Rapport Announces Pricing of Public Offering of Common Stock
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened
Via Stocktwits
Let's take a look at the stocks that are in motion in today's session.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Rapport Announces Proposed Public Offering of Common Stock
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-09-08: top gainers and losers in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Top stock movements in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Gold Moves Higher; Robinhood Shares Jump
 
Via Benzinga
Rapport Therapeutics, Planet Labs, QuantumScape, EchoStar And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Nasdaq Surges 150 Points; Planet Labs Shares Jump After Q2 Results
 
Via Benzinga
Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures
The company is working on a treatment for a form of epilepsy that tends to be difficult to control. 
Via Investor's Business Daily
Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year
Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety profile driving next steps. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Friday's after hours session: top gainers and losers
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Phibro Animal Health, Pure Storage, Snowflake, Build-A-Bear Workshop And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Rapport (RAPP) Q2 Net Loss Widens 47%
Via The Motley Fool
Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Narrower-Than-Expected Q2 2025 Loss Amid Clinical Progress
Rapport Therapeutics reports Q2 2025 net loss of $26.7M ($0.75/share), beating estimates. Focus remains on Phase 2a trial for RAP-219 in epilepsy, with results expected in September. Cash reserves... 
Via Chartmill
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development. 
Via MarketBeat
What's going on in today's session
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 
From Rapport Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.